+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating AZD0120, a dual-targeted CAR-T cell therapy against BCMA and CD19, compared with standard treatment regimens in people with relapsed refractory multiple myeloma RRMM. This Phase III open-label, randomized global trial aims to compare the effectiveness and safety of AZD0120 against four standard regimens DKd daratumumab, carfilzomib, dexamethasone, DPd daratumumab, pomalidomide, dexamethasone, PVd pomalidomide, bortezomib, dexamethasone, and Kd carfilzomib, dexamethasone. Participants will be randomly assigned to receive either AZD0120 or one of the four standard regimens chosen by their investigator. AZD0120 is a biological CAR-T cell therapy, while the standard regimens involve combinations of drugs administered according to routine care. The study evaluates treatment effectiveness over several years, including progression-free survival and minimal residual disease negativity. During the trial, participants will undergo regular assessments including laboratory tests and clinical evaluations to monitor disease status and treatment response. Key outcomes include progression-free survival and minimal residual disease negativity rates. Safety and effectiveness will be monitored over multiple years. The total study duration extends up to 5 years, with participants followed for outcomes such as overall survival and response rates.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination of two investigational drugs, avutometinib and defactinib, compared to standard treatments chosen by doctors in patients with recurrent low-grade serous ovarian cancer LGSOC who have progressed after prior platinum-based therapy. This Phase 3, international, randomized, open-label study aims to compare progression-free survival and also assess overall survival, safety, quality of life, and disease symptoms. The study is conducted by specialists in gynecological cancer. Participants will receive either the combination of avutometinib and defactinib or one of four standard treatments recommended for recurrent LGSOC. Avutometinib is given orally at 3.2 mg twice weekly for 21 days followed by 7 days off in a 28-day cycle, combined with defactinib given orally at 200 mg twice daily on the same schedule. The standard treatments include pegylated liposomal doxorubicin, paclitaxel, anastrozole, or letrozole, each administered according to their usual dosing schedules. Patients initially receiving standard treatment who experience disease progression may switch to the investigational drug combination. During the study, participants will have regular visits for treatment and follow-up assessments including laboratory tests and evaluations of tumor status. Researchers will monitor progression-free survival for up to 24 months and overall survival for up to 5 years. They will also assess response rates, duration of response, disease control, adverse events, blood drug levels, and quality of life using questionnaires. The total study duration may extend until 2031, with ongoing monitoring of health and symptoms throughout.

Age: 18Years +FEMALEPhase 3
105 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.

Age: 18Years +All GendersPhase 3
145 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations